Neurogene Inc (NGNE) Stock Forecast & Price Target

Neurogene is viewed favorably because NGN-401 is showing compelling durability and breadth in Embolden, with 8/10 patients meeting the pivotal composite endpoint at 12 months, 10/10 improving on CGI-I and gaining at least one milestone, and no milestone loss through up to 30 months. The safety profile at the 1E15 vg dose remains generally well tolerated across 35 treated patients, and the initiated PPQ campaign is on schedule for completion by YE26, supporting a potential BLA path. Financially, the recent ~$144M gross follow-on raised about ~$134.8M net, lifting pro forma cash to roughly $360.2M and extending runway into 1Q29, reducing financing risk ahead of the 2H27 data readout.

Neurogene is burdened by substantial development, regulatory, commercial, manufacturing, financing, and IP risk, with particularly acute concerns around NGN-401 safety after cases of HLH/hyperinflammatory syndrome at 1E15 vg and a registrational efficacy gap versus the 35% response rate required versus 80% observed to date. The outlook is further weakened by reversal of prior FDA alignment that EMBOLDEN data may support a BLA, while ICV administration may prove a higher adoption hurdle and Rett syndrome caregivers could defer a one-time therapy to preserve future options. Although the DCF implies an EV of $1.7B and a 55% probability of approval, the thesis remains negative because the company is still clinical-stage, is concentrated in NGN-401, and faces delays, unfavorable data risk, and long-term dilution risk.